Representative results of haploidentical studies. (A) Results from Perugia describing long-term EFS probability of AML patients transplanted in either remission or relapse. Reprinted from Aversa et al with permission.28 (B) Results from the European Group for Blood and Marrow Transplantation survey of 173 high-risk adult leukemia patients undergoing fully haploidentical transplantation in 49 centers. The figure describes LFS of AML patients according to disease status at time of transplantation (25 in CR1 and 148 in CR ≥ 2). Reprinted from Ciceri et al with permission.30 (C) An observational study based on data from the statistical center of the Center for International Blood and Marrow Transplant Research, summarizing the results of 584 patients in 151 center undergoing allogeneic transplantation for AML in first remission and unfavorable cytogenetics at diagnosis. The figure describes adjusted overall survival probability based on stem cell origin. Reprinted from Gupta et al with permission.98 As can be seen, the results presented are comparable and less favorable than that described for AML patients undergoing haploidentical hematopoietic transplantation in first CR. (D) The probability of DFS for ALL pediatric patients who received positive selected transplants from haploidentical donors (n = 28) or unmanipulated BMTs from matched unrelated donors (n = 18) while in remission. Reprinted from Lang et al with permission.32
